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Abstract
BACKGROUND—BRAF-V600E is the genetic lesion underlying hairy cell leukemia. We
assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy cell
leukemia who relapsed after or were refractory to purine analogues.
METHODS—We conducted in Italy and USA two phase-2 single-arm multicenter studies of
vemurafenib (960 mg twice daily) given for a median of 16 and 18 weeks, respectively. Primary
endpoints were complete remission rate and overall response rate. Patient enrollment was
completed (n=28) in the Italian trial in April 2013 and is still open (n=26/36) in the American trial.
RESULTS—Drug-related adverse events were usually of grade 1-2, and those most frequently
requiring dose reductions were rash and arthralgia/arthritis; secondary cutaneous tumors (treated
with simple excision) developed in 6/50 patients. Overall response rates were 96% (25/26
evaluable Italian patients) and 100% (24/24 evaluable American patients), obtained after a median
of 8 weeks and 12 weeks, respectively. Complete response rates were 34.6% (9/26) and 41.7%
(10/24), respectively. In the Italian trial, after a median follow-up of 23 months, the median
relapse-free and treatment-free survivals were respectively 19 and 25 months in complete
responders, and 6 and 18 months in partial responders. In the American trial, 1-year progression-
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free and overall survival were 73% and 91%, respectively. Frequent persistence of phospho-ERK+
bone marrow leukemic cells at the end of treatment suggests bypass MEK-ERK reactivation as a
resistance mechanism.
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CONCLUSIONS—A short oral course of vemurafenib proved safe and highly effective in
relapsed/refractory hairy cell leukemia patients (Funded by AIRC, ERC, Roche/Genentech and
others; EudractCT number: 2011-005487-13, ClinicalTrials.gov number NCT01711632).
Keywords
hairy cell leukemia; BRAF mutations; BRAF inhibitors; vemurafenib

INTRODUCTION
Hairy cell leukemia is a chronic mature B-cell malignancy with unique clinicopathologic
and biologic features1-4. Purine analogues (cladribrine; pentostatin) induce durable complete
remissions in ~80% of HCL cases5,6. However, 30-50% of patients relapse and respond
progressively less well to purine analogues7,8, which can also cause cumulative
myelotoxicity and immune-suppression. Thus, new therapeutic approaches are needed.
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Tiacci et al. discovered the V600E mutation of BRAF, a kinase commonly mutated in solid
tumors9, as the key genetic lesion of hairy cell leukemia10,11, and Chung et al. reported that
this mutation is acquired in the hematopoietic stem cell compartment12. Tiacci et al. showed
that, as in other BRAF-mutated neoplasms13, the V600E mutation in hairy cell leukemia
constitutively activates the MAPK pathway14,15. The same group demonstrated in vitro16
that BRAF inhibitors reverse the unique molecular signature2 and morphology of patients'
hairy cells, and potently induce their apoptosis, thus establishing BRAF-V600E as an
attractive therapeutic target in hairy cell leukemia. Moreover, anti-leukemic activity of
BRAF inhibitors has been anecdotally reported in these patients17,18.
We conducted two phase-2 multicenter clinical trials, in Italy and USA, to define the
efficacy and safety of an oral BRAF inhibitor, vemurafenib19, in patients with relapsed or
refractory HCL. Patients in the Italian trial completed enrollment in April 2013 and have a
median follow-up of almost 2 years from the end of treatment. The American trial has not
yet completed patient enrollment but already met its primary endpoint (overall response
rate). Here we report the results of both trials.

MATERIALS AND METHODS
Patients
In the Italian trial, 28 patients were enrolled (Table S1) meeting the following criteria:
refractoriness to a purine analogue (no response or relapse within 1 year following
treatment; n=6); early relapse after a purine analogue (between 1 and 2 years from the first
course, or within 4 years from a second or later course, n=20; or whenever in case of
significant bone marrow hypoplasia at relapse, n=1); or severe side effects from a previous
purine analogue (n=1). Patients had to have Hb <11.0 g/dl and/or neutrophils <1,500/mm3
and/or platelets <100,000/mm3. The diagnosis was centrally confirmed by two authors (BF,
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ET) through annexin-A1 immunostaining of marrow biopsy20, BRAF-V600E detection by
allele-specific PCR11 and flow cytometry. Further details are provided in the study protocol
available at NEJM.org.
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In the American trial, 26 patients were enrolled (Table S2) meeting the following criteria:
refractoriness to a purine analogue (as defined above); early relapse (between 1 and 2 years)
after the first course of purine analogue; or ≥2 relapses after 2 years from a third or later
course of purine analogue. Patients had to have neutrophils ≤1,000/mm3, Hb ≤10g/dl, or
platelets ≤100,000/mm3. BRAF-V600E was assessed with immunohistochemistry, PCR/
Sanger sequencing and/or MSKCC IMPACT assay21 (the latter done in all patients) in a
CLIA-certified laboratory. Further details are provided in the study protocol available at
NEJM.org.
Study design
The Italian trial (B. Falini: principal investigator) is a phase-2, single-arm, multicenter study
sponsored by the Institute of Hematology, University of Perugia, and designed by two
academic investigators (BF and ET). Roche provided vemurafenib and an unconditional
research grant. The planned enrollment of 28 patients was completed in 11 months (May
2012-April 2013) at 8 centers. Patients received oral vemurafenib 960 mg twice daily for a
minimum of 8 weeks and, if not achieving complete response, a maximum of 16 weeks
(Supplementary Figure 1). The first 3 patients received 20 weeks of vemurafenib. The
primary endpoint was complete response. Secondary endpoints included time to response,
relapse-free survival and safety. We also evaluated overall response, progression-free
survival (PFS), treatment-free survival (TFS) and pharmacodynamic biomarkers.
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The American trial (J. Park: principal investigator), a phase-2 single-arm multicenter study,
enrolled patients consecutively from 1/2013-2/2015 at 6 sites. Patients received oral
vemurafenib 960 mg twice daily, on a continuous schedule for 3 months. Patients with
residual disease (by morphology or immunohistochemistry for CD20, PAX5, DBA44 and
tartrate-resistant alkaline phosphatase) were allowed to receive up to 3 additional months of
vemurafenib. The primary end point was overall response after 3 months of vemurafenib.
Secondary end points were overall survival, progression-free survival, time-to-relapse and
pharmacodynamic analyses.
In both trials, at disease relapse, defined by peripheral blood counts low enough to meet the
respective initial eligibility criteria, retreatment with vemurafenib was allowed, for up to 12
weeks (Italian trial) and until disease progression or unacceptable toxicity (American trial).
Study assessments
Adverse events were graded according to the NCI Common Terminology Criteria for
Adverse Events (CTCAE) v4.03. Neoplastic cutaneous lesions were surgically excised but
did not mandate dose modifications.
In the Italian trial, response assessments (blood counts, spleen size, marrow biopsy and
aspirate) were done monthly during treatment (together with a dermatologic examination)
and every 3 months during follow-up (except the marrow evaluation, done every 6 months).
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Marrow and peripheral blood samples were centralized at the Institute of Hematology,
University of Perugia. The Hairy Cell Index (Supplementary Methods) in the marrow biopsy
was calculated as previously described22.
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In the American trial, marrow assessments were obtained after 1 and 3 months of
vemurafenib and at end of treatment. For patients with splenomegaly at enrollment,
abdominal CT was performed at baseline and at 3 months. All patients underwent
dermatologic examination at baseline, after 1 month of vemurafenib, and every 3 months
thereafter for at least 1 year after drug discontinuation.
In both trials, complete response required resolution of any cytopenias (neutrophils
≥1,500/mm3, platelets ≥100,000/mm3, Hb ≥11 g/dl), no evidence of hairy cells in the
peripheral blood and marrow biopsy by non-immunologic stains, and no splenomegaly.
Partial remission required: resolution of cytopenias; ≥50% splenomegaly reduction; and
≥50% reduction of leukemic infiltration in both the marrow and peripheral blood. In both
trials, relapse after complete or partial remission was defined as re-appearance of
cytopenia(s) on at least two consecutive occasions (the first of which counted as relapse
date).
Pharmacodynamic analyses
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Changes in leukemia cell morphology during vemurafenib exposure and bone marrow ERK
phosphorylation at the end of treatment (in a blinded fashion with respect to patients'
outcome post-treatment) were assessed as described14,16. Leukemia disease burden was
assessed by serial flow cytometric analysis of peripheral blood or marrow mononuclear
cells5,23. DNA from peripheral blood mononuclear cells was used to quantify BRAF-V600E
allele burden using droplet digital PCR. Soluble IL2RA and IL1R-type II were measured in
serum24. Targeted genomic analysis was performed in peripheral blood mononuclear cells as
described25. Further details are provided in Supplementary Methods.
Statistical analysis
A Simon’s minimax two-stage design27 was adopted in both trials. Full details are provided
in Supplementary Methods.

RESULTS
Patients
The characteristics of all patients (n=54) are shown in Table 1 and Tables S1-S2. Six patients
with disease refractory to a purine analogue were in the Italian study and 1 in the American
one, and had undergone a median of 2.5 and 1 prior therapies before vemurafenib,
respectively. Patients relapsed early and/or repeatedly after purine analogues (21 and 25,
respectively) had received a median of 4 and 3 prior therapies, respectively. Fifty-four
percent (15/28) of the Italian patients were refractory to the immediate prior therapy as were
41% (9/22) (41%) of the American patients.
In the Italian trial, 26/28 patients completed the planned treatment (median weeks of
vemurafenib: 16, range 8-20). Two patients went off-study after ≤1 week due to drugN Engl J Med. Author manuscript; available in PMC 2016 April 29.
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unrelated acute myocardial infarction and to consent withdrawal after grade-3 drug-related
reversible pancreatitis.

Europe PMC Funders Author Manuscripts

In the American trial, 24/26 patients had a median of 4.5 (range 3-6) months of treatment.
One patient died from drug-unrelated progressive pneumonia after 23 days on treatment, and
another one withdrew consent after 1 month due to grade-3 drug-related reversible
photosensitivity.
Adverse events
Table 2 shows drug-related adverse events of grade ≥2 observed in ≥1 patient in each trial.
Tables S3-S4 shows all adverse events of any grade (including those not considered drugrelated in the Italian study).
In both trials, common vemurafenib-related adverse events, mostly of grade 1-2 and all
reversible, included skin toxicities (especially rash and photosensitivity), arthralgias/arthritis,
pyrexia and bilirubin increase. Other relatively frequent drug-related adverse events
(recorded in one and/or the other study) were skin papillomas, alopecia, palmar/plantar
hypercheratosis/dysesthesia, fatigue, and increase of serum lipase (including 2 patients with
grade-3 pancreatitis), transaminases, alkaline phosphatase or fibrinogen.
In the Italian study, cutaneous basal cell carcinomas developed in 2 patients (one with a
previous history of basal cell carcinoma) and a cutaneous superficial melanoma occurred in
one patient. In the American study, cutaneous squamous cell carcinomas developed in 3
patients (all with a previous history of squamous cell carcinoma), and a cutaneous basal cell
carcinoma develope in 1 patient. All these tumors were managed by simple excision.
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A slight transient Hb decrease was noted in 10 Italian patients within the first 6 weeks of
treatment, and neutropenia in 1 American patient.
In the Italian trial, the planned vemurafenib dose (twice daily 960 mg) was reduced for ≥3
weeks in 17 instances involving 15/26 (58%) patients to twice daily 720 mg (9 patients), 480
mg (3 patients) or 240 mg (3 patients); toxicities related to these events were mainly rash in
6 patients and increased creatinine or bilirubin, arthralgia, pancreatitis, and palmo-plantar
dysesthesia, each in 1 patient.
In the American trial, 13 patients (50%) required dose reductions to twice daily 720 mg (2
patients), 480 mg (10 patients) or 240 mg (1 patient). Adverse events leading to dose
modifications were arthralgia (5 patients), rash (5 patients), photosensitivity (1 patient),
neutropenia (1 patient), and AST/ALT elevations (1 patient).
Response rate
The overall response rate was 96% (25/26 evaluable Italian patients) and 100% (24/24
evaluable American patients) in the two trials. The unusual presenting features of the only
non-responding patient are described in Supplementary Results.
Complete and partial response rates were also similar in both trials. The Italian study
showed 34.6% CRs (9/26 patients) and 61.4% PRs (16/26), after a median of 8 weeks (Table
N Engl J Med. Author manuscript; available in PMC 2016 April 29.

Tiacci et al.

Page 7

Europe PMC Funders Author Manuscripts

S1). Complete and partial responders included 1 and 5 primary refractory ones, respectively.
Notably, 4 complete and 10 partial responders were resistant to the last prior treatment.
Median time for recovery of platelets (≥100,000/mm3), neutrophils ( ≥1,500/mm3) and Hb
(≥11 g/dl) was 2, 4 and 8 weeks, respectively. Reversion of symptomatic splenomegaly and
clearance of leukemia cells from the blood (by cytomorphology) usually occurred within 2
weeks. A significant decrease in marrow leukemic infiltration was observed at the earliest
time point evaluated (4 weeks) (not shown). However, in all complete responders,
immunohistochemistry showed minimal residual disease (≤10%) at the end of treatment
(Figure 1A-B).
In the American trial, after 3 months of vemurafenib 10/24 (41.7%) patients achieved
complete and14/24 (58.3%) a partial response (Table S2). Most patients achieved recovery
of neutrophils (>1,000/mm3), Hb (>10g/dl), and platelets (>100,000/mm3) by 28 days
(Figure 2A). In patients receiving twice daily vemurafenib 480 mg for >1 month (n=10),
similar complete and partial response rates were observed (6/10 and 4/10, respectively).
In unplanned exploratory analyses of both studies, treatment duration did not appear to
influence response depth (Supplementary Results), and complete rate was not influenced by
prior splenectomy, marrow disease burden, refractoriness to the last treatment or number of
prior therapies (Tables S1-S2 and not shown).
Response duration
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In the Italian study, the median follow-up for the 25 responding patients was 23 months
(range 7-28) from the last vemurafenib dose. Median relapse-free survival was 9 months,
being significantly longer in complete than in partial responders (19 and 6 months,
respectively; p-value 0.006; HR 0.26, 95% CI 0.10-0.68; Figure 1C). Median treatment-free
survival was 21.5 months in all 26 evaluable patients, and (with the limitation of small
numbers) did not differ between complete and partial responders (25 and 18 months,
respectively; p-value 0.21; Figure 1C). Indeed, of the 20 relapsed patients (5 after complete
and 15 after partial responses), 7 did not require therapy at a median of 15 (range 4-18)
months following relapse, as their cytopenia(s) are stably mild (median Hb 14.2 g/dl, range
12.4-17.5 g/dl; median neutrophils 1122/mm3, range 938-1724/mm3; median platelets:
86,000/mm3, range 63,000-269,000/mm3). Conversely, in 13/20 relapsed patients
cytopenia(s) worsened requiring an anti-leukemic treatment at a median of 5 (range 0-16)
months after relapse. Five of 25 patients (4 complete 1 partial responder) have not relapsed
at the last follow-up (23-25 months post-treatment). Three of 4 complete responders showed
no morphologic evidence of hairy cell leukemia in their last marrow biopsy at 13, 19 and 24
months, respectively, whereas the other patient lost the histologic complete response status
at 12 months but maintained normal blood counts at the last follow-up (24 months). In
unplanned exploratory analyses, relapse-free and treatment-free survival did not differ
between patients receiving (n=18) or not receiving (n=7) additional treatment with
vemurafenib after achievement of their best response, or between patients requiring (n=14)
or not requiring (n=11) a dose reduction (not shown). However, as compared to the 18 nonsplenectomized patients, the 7 splenectomized patients had shorter relapse-free survival
(median of 11 and 6 months, respectively; HR 3.5, 95% CI 1.04-12.1; p-value 0.04) and
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treatment-free survival (median of 25 and 11 months, respectively; HR 6.6, 95% CI 1.6-28;
p-value 0.010).
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In the American trial, median follow-up from the first vemurafenib dose among survivors
was 11.7 months (range, 1.3 – 25.4). At one year, progression-free survival was 73% (95%
CI: 55-97) and overall survival was 91% (95% CI: 79-99) (Figure 2B). Disease progression
developed in 7 (3 complete and 4 partial responders) of 24 patients (29%) (Table S2). At one
year following response, the cumulative incidence of relapse was 27% (95% CI: 7-51).
In both trials, vemurafenib retreatment at relapse produced some responses, detailed in
Supplementary Results.
Pharmacodynamic analyses and resistance mechanisms
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Hairy cell leukemia cells exposed in vitro to vemurafenib downregulate CD25 and lose their
surface projections16. Consistently, blood and/or marrow flow cytometry documented loss of
surface CD25 in a large fraction of leukemia cells at one or more time points during therapy
in 15/19 (79%) evaluable Italian patients (including one already reported16) (Figure 3A),
suggesting that measurement of surface or soluble CD25 may underestimate the residual
HCL burden during vemurafenib treatment. Interestingly, in one patient with marked
lymphocytosis, leukemic cells showed a clear smoothing of the cell membrane 2 and 3 days
after starting vemurafenib (Figure 3B). Moreover, in 13/26 Italian patients a marrow biopsy
taken the day after therapy completion was evaluable for phospho-ERK/PAX5 double
immunostaining. In 6/13 patients (all partial responders), residual hairy cells (PAX5+) still
expressing phospho-ERK were observed despite prolonged (16-20 weeks) exposure to
vemurafenib (Figure 3C, left). In 7/13 patients (2 complete and 5 partial responders after
12-20 weeks of treatment), residual leukemic cells did not detectably express phospho-ERK
(Figure 3C, right). Median progression-free survival in patients with or without residual
phospho-ERK+ leukemic cells was 7.75 months (range 5-13) and 13 months (range 7.5-24),
respectively (p-value 0.004; HR 10.3, 95% CI 2.1-51). Interestingly, residual disease
measured by the hairy cell index was higher in patients with persistent versus undetectable
phospho-ERK expression in leukemic cells (average hairy cell index: 0.139 versus 0.054; pvalue 0.026, two-sided Mann-Whitney test). Thus, persistent ERK phosphorylation in
residual hairy cells at the end of treatment may indicate a greater residual disease burden and
a shorter progression-free survival, suggesting MEK/ERK reactivation is a resistance
mechanism to vemurafenib.
In the American trial, pre-vemurafenib the mean percentage of leukemic cells in blood and
marrow mononuclear cells by flow cytometry was 16.0% and 16.8%, respectively. This
decreased to 3.4% and 6.9%, respectively, after 1 month of treatment (p-value <0.05 - Figure
2C) and to 0.74% and 4.2%, respectively, by 3 months. Bone marrow hairy cells decreased
even further after 6 months to a mean of 1.3% (Figure 2C). Likewise, digital PCR revealed a
>100-fold decrease of BRAF-V600E allele burden in peripheral blood mononuclear cells
after 3 months of vemurafenib (p=0.0001 compared to pretreatment; Figure 2D).
Accordingly, phosphorylated ERK1/2 rapidly decreased in marrow biopsies after 1 month of
vemurafenib (Figure S3A). Finally, in all patients serum levels of soluble IL2RA and IL1R
type II, well established hairy cell leukemia biomarkers27,28, markedly declined, relative to
N Engl J Med. Author manuscript; available in PMC 2016 April 29.
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the baseline, by a mean of 30% and 27%, respectively, within 24 hours of vemurafenib and
by ≥95% after 3 months (Figure S3B-C).
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In one American patient refractory to vemurafenib retreatment, targeted sequencing of 300
genes (Table S3) identified 2 separate activating subclonal KRAS mutations (along with a
new RUNX1 mutation) at relapse after the initial vemurafenib treatment, in addition to the
recurrence of the BRAF-V600E mutation. KRAS mutations were not seen before
vemurafenib or at remission (day 120) despite high KRAS sequencing coverage (range:
496X-1165X) (Figure 4B; Table S5). Because in BRAF-V600E mutant malignancies
activating RAS mutations represent a known mechanism of vemurafenib resistance through
MEK/ERK rephosphorylation29, the KRAS mutations newly acquired in this patient at
relapse, although subclonal, likely contributed to the subsequent insensitivity to vemurafenib
(Figure 4C).

DISCUSSION
In both trials, an oral course of vemurafenib (960 mg twice daily for 16-18 months) was
rapidly and highly effective (96%-100% response rate) with low-grade toxicity in hairy cell
leukemia patients who were not only heavily pre-treated but often (41%-53% of cases)
refractory to the last prior therapy. The median time to response was 8 weeks in the Italian
trail and 12 weeks in the American trial. Further treatment did not appear to improve
response depth or duration. Retreatment with vemurafenib at relapse was effective, although
to a lesser extent in Italian patients relapsing after partial response versus after complete
response.
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Unlike vemurafenib dosing of indefinite duration as in metastatic melanoma30-32, we limited
initial vemurafenib treatment to a few months (even if this perhaps reduced response depth
and/or duration) due to the concern of vemurafenib-induced secondary tumors33-35.
Although the latter mostly affect the skin and are of low malignant potential, their
development may be less acceptable in an indolent leukemia (however refractory or multiply
relapsed) compared to metastatic melanoma.
The response rate, depth and duration in hairy cell leukemia was higher than in metastatic
melanoma30-32, possibly due to the less complex hairy cell leukemia genome landscape
(dominated by BRAF-V600E10) and the much lower proliferative index (≤1%) of hairy cell
leukemia versus metastatic melanoma36-37. However, in both trials marrow residual hairy
cells with their associated BRAF-V600E allele burden were consistently present at the end
of treatment, even after complete response. In about half of evaluable Italian patients, these
cells exhibited persistent phospho-ERK expression despite prolonged ongoing exposure to
vemurafenib, which appeared to correlate with a higher residual leukemic burden and shorter
progression-free survival. This suggests that, in at least some patients, leukemic cells
develop alternative mechanisms for reactivating MEK/ERK to bypass BRAF blockade. In
vitro studies from the Italian group suggest that the marrow microenvironment might oppose
vemurafenib-induced ERK dephosphorylation and apoptosis16. Intriguingly, it was
proposed38 that, passing through the vitronectin-rich splenic red pulp, hairy cells receive
vitronectin-mediated pro-apoptotic signals that are transduced by p38/JNK activation but are
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overcome by concomitant anti-apoptotic signals from constitutive MEK-ERK activation. We
noted that prior splenectomy appeared to associate with shorter response duration. Thus,
lack of hairy cell recirculation through the spleen resulting in their continuous homing to the
protective marrow microenvironment may favor the persistence of ERK phosphorylation in
leukemic cells at the end of treatment, a feature also apparently associated with a shorter
response duration. Furthermore, one patient in the American trial acquired at relapse two
activating KRAS mutations likely contributing to disease progression on vemurafenib
retreatment.
Vemurafenib-related adverse events were manageable and similar to those observed in
melanoma (e.g., rash, arthralgias and secondary cutaneous tumors). Importantly, lack of
significant myelotoxicity makes vemurafenib an ideal salvage treatment for multiply
relapsed hairy cell leukemia patients with pancytopenia and scarce marrow reserve due to
previous chemotherapies.
Lower vemurafenib doses (e.g., 240 mg twice daily) from the beginning of treatment proved
effective in anecdotal relapsed/refractory hairy cell leukemia patients17. In our studies, the
starting dose, 960 mg twice daily, was reduced only if toxicity occurred, and mostly to 720
mg (in Italian patients) or 480 mg (in American patients) twice daily, followed sometimes by
re-escalation. Prospective clinical trials are needed to formally evaluate toxicity, response
rate and survival with lower vemurafenib doses and/or longer treatment durations. Clinical
trials are also warranted to evaluate the other clinical BRAF inhibitor, dabrafenib, which in
vitro studies from the Italian group16 and single case reports18,39 suggest to be effective in
refractory/relapsed HCL.
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We used vemurafenib as single agent. However, BRAF inhibitors could be combined with
anti-CD20 monoclonal antibodies (e.g. rituximab) to potentially eradicate BRAF inhibitorresistant HCL cells. The finding of MAPK pathway reactivation as a likely mechanism of
resistance to vemurafenib in some patients also establishes a rationale for combined BRAF
and MEK blockade, as successfully exploited in metastatic melanoma40.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Response depth and duration in the 25 patients of the Italian trial responding to
vemurafenib

(A) Hematoxylin-eosin staining of a BM biopsy from a patient showing infiltration by
leukemic HCL cells with wide, clear cytoplasm recognizable by morphology at baseline (left
panel), but not after 8 weeks of vemurafenib (right panel). (B) CD20 immunostaining of the
same BM biopsy showing ~75% leukemic infiltration at baseline (left panel), and only few
(≤10%) residual scattered hairy cells after 8 weeks of vemurafenib (right panel). (C)
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Relapse-free (left) and treatment-free survival (right) of patients obtaining a CR (black line)
or PR (red line).
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Figure 2. Effect of vemurafenib on peripheral blood counts, survival, flow cytometric
enumeration of hairy cells, and BRAFV600E allele burden

(A) Median value of the absolute neutrophil count, hemoglobin and platelet cell counts of
the 24 evaluable patients over time after initiating vemurafenib treatment. Error bars denote
the upper and lower limits. (B) The probability of progression-free survival and overall
survival for all 26 patients. Tick marks indicate censored data. (C) Mean percentage of HCL
cells in peripheral blood and bone marrow mononuclear cells over time of patients from this
study (± standard error of mean (SEM)). Mean percentage of HCL cells decreased with each
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period of vemurafenib therapy shown (p<0.05 comparing percentage of HCL cells for each
time point on therapy relative to pretreatment values). (D) Ratio of the concentration of
BRAFV600E:BRAF wildtype alleles (log10) in DNA from peripheral blood mononuclear
cells pretreatment with vemurafenib and following 3 months of vemurafenib. The ratios are
displayed as box-and-whisker plots with the median value as the middle bar, the ends of the
boxes as upper and lower quartile values, and ends of whiskers as highest and lowest values.
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Figure 3. Phenotypic and molecular changes of HCL cells during treatment with vemurafenib in
the Italian trial

(A) Flow cytometry dot plots of a patient’s BM aspirate gated on CD45 cells and showing at
baseline (left panels) CD25 expression by 94% of leukemic cells (CD19+/CD103+, upper
row; CD19+/CD25+, bottom row). A progressively loss of CD25 expression (but not of
CD19 or CD103 expression) is seen over 1 and 2 weeks of treatment with vemurafenib
(down to 21% and 12%, respectively; middle and right panels, respectively). The remaining
cells (red events) are normal CD45+ hematopoietic cells. (B) Left panels. May-Grümwald-
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Giemsa staining of a patient’s peripheral blood smear featuring leukemic cells rich in hairy
projections at baseline (top), but not after 2 days of vemurafenib treatment (bottom). Right
panels. Confocal fluorescence microscopy analysis of blood leukemic cells purified from the
same patient shows prominent surface projections (stained in green by phalloidin) at
baseline (top), but not after 3 days of vemurafenib treatment (bottom); these changes are
clearly evident both in electronically magnified two-dimensional and three-dimensional
reconstructed images of representative cells; (C) Double immunostaining of BM biopsy
taken the day after the end of treatment and double stained for PAX5 (a B-cell marker; in
brown) and phospho-ERK (pERK; in blue). In some responding patients (one exemplified in
the left panel) persistence of pERK+ leukemic hairy cells is observed; conversely, in other
patients (one exemplified in the right panel) residual hairy cells do not detectably express
phospho-ERK, with stromal cells strongly positive for phospho-ERK as internal positive
control.
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Figure 4. Serial genomic analysis reveals activating KRAS mutations associated with
development of acquired vemurafenib resistance in BRAFV600E-mutant HCL

(A) Serial flow cytometric analysis for HCL cells in peripheral blood mononuclear cells
throughout the initial course of therapy (days 0-180) and vemurafenib retreatment (days
260-320). Percentages in FACS plots denote percentage of HCL (CD19/CD103) cells
amongst PB MNCs. (B) Somatic mutations identified in PB MNCs following 0, 120, and
260 days of vemurafenib administration. The variant allele frequency (%) is shown for
mutations seen at each timepoint. (C) Graph of percentage of HCL cells in peripheral blood
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(left axis) and total WBC count (right axis). Shaded areas represent periods of vemurafenib
treatment and retreatment.
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Table 1

Baseline demographic and clinical characteristics of the patients
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Characteristic

Italian Trial (N=28)

American Trial (N=26)

Age
Median – yr

57

62

Range – yr

27 - 84

44 - 80

Median

3

3

Range

1 -12

1-8

Number of previous therapies

9*

Refractory to immediate prior therapy
Yes

15

No

12

13*

Prior splenectomy – % of patients
Yes

28

19

No

69

81

Median hairy cell involvement in bone marrow (range)¶ - %

82.5 (40 - 95)

80 (25 – 100)

Median absolute neutrophil count (range), – ×103/mm3

0.8 (0.2 - 5.7)

0.8 (0.2 – 4.8)

Median hemoglobin (range), – g/dl

12.2 (8.2 - 17)

10.5 (8.2 – 14.4)

70 (6 - 306)

78 (26 – 238)

Extent of HCL

Median platelet count (range), –

×103/mm3
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*

The data on refractoriness to immediate prior therapy was available in 22 patients.

¶

By immunohistochemistry.
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Table 2

Drug-related adverse events of grade ≥2*
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Adverse Event

Italian trial

American Trial

No. of patients (%)

No. of patients (%)

Grade 2

Grade 3

Grade 4

Total

Grade 2

Grade 3

Grade 4

Total

Arthralgia/Arthritis

10 (36)

2 (7)

0

12 (43)

8 (31)

0

0

8 (31)

Rash/Erythema

11 (39)

2 (7)

0

13 (46)

11 (42)

5 (19)

0

16 (62)

Cutaneous basal cell carcinoma

2° (4)

0

0

1 (4)

1 (4)

0

0

1 (4)

Cutaneous superficial melanoma

0

1 (4)

0

1 (4)

0

0

0

0

Cutaneous squamous cell carcinoma

0

0

0

0

3 (11)¶

0

0

3 (11)

Skin papillomas

2 (7)

0

0

2 (7)

0

0

0

0

Photosensitivity reaction

2 (7)

0

0

7 (11)

0

2 (8)

0

2 (8)

Hyperkeratosis

3 (11)

0

0

3 (11)

0

0

0

0

Panniculitis

2 (7)

0

0

2 (7)

0

0

0

0

Pancreatitis

1^ (4)

2 (7)

0

3 (11)

0

0

0

0

Pancreatic enzymes increased

1 (4)

1 (4)

0

2 (7)

0

0

0

0

Hyperbilirubinaemia

2 (7)

1 (4)

0

3 (11)

3 (11)

0

0

3 (11)

Transaminases increased

1 (4)

0

0

1 (4)

3 (11)

1 (4)

0

4 (15)

0

0

0

0

0

2 (8)

0

2 (8)

Pain to the extremities

2 (7)

0

0

2 (7)

2 (8)

0

0

2 (8)

Headache

1 (4)

0

0

1 (4)

0

0

0

0

Blood creatinine increased

2 (7)

0

0

2 (7)

1

0

0

1 (4)

Seborrhoeic keratosis

2 (7)

0

0

2 (7)

0

0

0

0

Asthenia

1 (4)

0

0

1 (4)

0

2 (8)

0

2 (8)

Musculoskeletal pain

1 (4)

0

0

1 (4)

0

0

0

0

Abdominal pain

Alkaline phosphatase increased
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1 (4)

0

0

1 (4)

0

0

0

0

Pyrexia

0

0

0

0

0

1 (4)

0

1 (4)

Nausea

0

0

0

0

1 (4)

0

0

1 (4)

Alopecia

0

0

0

0

1 (4)

0

0

1 (4)

*

Occurring in at least 1 patient.

°

In one patient two basal cell carcinomas developed; the other patient had a previous history of basal cell carcinoma.

¶

All 3 patients had previous history of squamous cell carcinoma.

^

Lipase and/or amylase elevation only (no clinical symptoms nor radiological abnormalities).
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